featured-image

SHANGHAI , May 29, 2024 /PRNewswire/ -- Recently, Frost & Sullivan released the report "The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-scale Production of Biologics". I. CDMOs are advancing the biopharmaceutical industry with superior biomanufacturing capabilities According to Frost & Sullivan analysis, production expansion for a more complex category of biologics, is facilitated by the flourishing industry, accelerated drug approvals, and booming global demand for biosimilars.

This is an opportunity for biologics CDMOs who can address the high costs of self-built production lines, limited experiences in R&D and production, and other challenges faced by traditional pharmaceutical companies. The global market size of biologics CDMOs has grown significantly from US$13.3 billion in 2018 to US$29.



3 billion in 2022 and is projected to reach US$58.1 billion by 2026 and US$100.4 billion by 2030.

II . CDMOs are shifting towards scale production, flexible capacity, diverse product offerings, and customized services With highly flexible biomanufacturing capabilities, CDMOs are expanding businesses to cover more client groups, drug types, and regions. CDMOs serve clients of various scales including biopharmas and biotechs As biopharmas encompass R&D, production, and commercialization, many favor an asset-light strategy that divests production activities and rely on outsourcing services to reduce costs.

Small and medium-sized biotechs excel in innovation an.

Back to Health Page